Home Medical 3D Systems improves radiotherapy targeting with VSP Bolus

3D Systems improves radiotherapy targeting with VSP Bolus

3D Systems announced its entry into the radiation oncology market with FDA 510(k) clearance of VSP Bolus, a solution designed to deliver high-quality patient-specific radiotherapy treatment accessories. As the latest addition to the company’s VSP portfolio of personalized medical devices, VSP Bolus is the only solution on the market that offers a full design and production service based on the patient’s treatment plan. As a result, radiotherapy providers do not need specialized design software and expertise, allowing them to focus directly on patient treatment and care. 3D Systems’ deep experience in additive manufacturing of medical devices enables the company to deliver 3D-printed, biocompatible patient-specific boluses that can improve therapy modulation as well as patient comfort.

3D Systems’ VSP Bolus solution delivers high-quality, patient-specific devices that contour to the patient’s anatomy, enabling more efficacious treatment and a more comfortable experience.

Approximately 50% of patients diagnosed with cancer will receive radiotherapy as part of their treatment. To help target the radiation during treatment, the provider (e.g., medical physicist, dosimetrist, radiation oncologist) will use a bolus—a flexible device that conforms to the patient’s skin. Off-the-shelf boluses can often leave gaps between the device and the patient’s anatomy, which can result in insufficient dosing and may also expose adjacent anatomy to undesired radiation. With VSP Bolus, 3D Systems can design and deliver boluses that conform to a wide range of anatomies. The process begins with the patient’s imaging data and input from the radiotherapy professional. Using this information, VSP Bolus is designed at the requested material thickness to optimize the radiotherapy targeting. With these capabilities built into the solution, radiotherapy professionals are freed from the time-consuming task of creating the design and fabricating the accessory themselves. Once designed, 3D Systems’ engineers employ the company’s additive manufacturing solutions to produce a high-quality bolus from a soft material that contours to the patient’s anatomy, enabling more efficacious treatment and a more comfortable experience.

Our new VSP Bolus product expands our capabilities to address yet another incredibly important application for personalized healthcare,” said Menno Ellis, executive vice president, healthcare solutions, 3D Systems. “While radiotherapy has become recognized as a common course of treatment for cancer diagnoses, each case is as unique as each patient. Blending the experience of our biomedical engineers, our biocompatible materials, 3D printing technology, and best-in-class digital workflows, we are able to both design and produce patient-specific devices to help improve the delivery of radiotherapy treatment.”

As a pioneer in personalized healthcare solutions, 3D Systems has worked with surgeons over the last decade to plan more than 140,000 patient-specific cases, and manufacture more than two million implants and instruments for 100+ CE-marked and FDA-cleared devices from its world-class, FDA registered, ISO 13485-certified facilities in Littleton, Colorado, and Leuven, Belgium. 3D Systems will showcase its solutions, including VSP Bolus, at the RSNA Medical 3D Printing in Practice event to be held April 22-24 in Chicago, Illinois.

Headline picture: 3D Systems’ VSP Bolus solution delivers high-quality, patient-specific devices that contour to the patient’s anatomy, enabling more efficacious treatment and a more comfortable experience.

(c) Picture & link: www.3dsystems.com


Subscribe to our Newsletter

3DPResso is a weekly newsletter that links to the most exciting global stories from the 3D printing and additive manufacturing industry.

Privacy Policy*
 

You can find the privacy policy for the newsletter here. You can unsubscribe from the newsletter at any time. For further questions, you can contact us here.